FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Polascik

Research Profile

Disorders

Chemicals & Drugs

Prostate Specific Antigen

Procedures

Anatomy

Prostate

Concepts & Ideas

Co-author Network

Publications

TOP 3
Maria Azrad; Dean E Brenner; Mark Dewhirst; John Madden; Judd W Moul; Thomas J Polascik; Mack T Ruffin; Denise Clutter Snyder; Robin T Vollmer; Wendy Demark-Wahnefried
Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer.
Qiang Fu; Judd W Moul; Vladimir Mouraviev; Leon Sun; Donghua Xie; Lionel Bañez; Thomas J Polascik
Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance.
M R Abern; Lionel L Bañez; M R Bassett; M N Ferrandino; Stephen J Freedland; Thomas J Polascik; Cary N Robertson; M Tsivian; Judd W Moul
Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Polascik (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Maria Azrad; Dean E Brenner; Mark Dewhirst; John Madden; Judd W Moul; Thomas J Polascik; Mack T Ruffin; Denise Clutter Snyder; Robin T Vollmer; Wendy Demark-Wahnefried
Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer.
Journal of medicinal food 2013;16(4):357-60.
2013: Qiang Fu; Judd W Moul; Vladimir Mouraviev; Leon Sun; Donghua Xie; Lionel Bañez; Thomas J Polascik
Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance.
Medical oncology (Northwood, London, England) 2013;30(1):326.
2013: M R Abern; Lionel L Bañez; M R Bassett; M N Ferrandino; Stephen J Freedland; Thomas J Polascik; Cary N Robertson; M Tsivian; Judd W Moul
Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center.
Prostate cancer and prostatic diseases 2013;16(1):85-90.
2013: M Tsivian; P Qi; M R Abern; Lionel L Bañez; L Gerber; C J Keto; Judd W Moul; Thomas J Polascik
African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center.
Prostate cancer and prostatic diseases 2013;16(1):91-4.
2013: M Tsivian; Jorge R Caso; Masaki Kimura; Thomas J Polascik
Renal tumors in solid organ recipients: clinical and pathologic features.
Urologic oncology 2013;31(2):255-8.
2013: M Tsivian; Michael R Abern; Thomas J Polascik
Evolution of the concept of focal therapy for prostate cancer.
Oncology (Williston Park, N.Y.) 2013;27(1):64-8, 70; discussion 70.
2012: Qiang Fu; Judd W Moul; Vladimir Mouraviev; Leon Sun; Dongha Xie; Lionel L Bañez; Thomas J Polascik
Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer.
Medical oncology (Northwood, London, England) 2012;29(5):3339-44.
2012: Masaki Kimura; Bridget F Koontz; Judd W Moul; Lionel L Bañez; Jorge R Caso; Craig F Donatucci; Leah Gerber; Cagri Senocak; Zeljko Vujaskovic; Thomas J Polascik
Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.
BJU international 2012;110(11 Pt C):E931-8.
2012: Adam C Mues; Ravi Munver; Stephen Nakada; Zhamshid Okhunov; Sutchin R Patel; Thomas J Polascik; Arieh Shalhav; W Bruce Shingleton; M Tsivian; J Stuart Wolf; Ketan K Badani; Kurdo Barwari; Sara L Best; Vincent G Bird; Jeffrey A Cadeddu; Ralph V Clayman; Jean de la Rosette; Joseph A Graversen; Emilie K Johnson; Louis Kavoussi; Ruslan Korets; Pilar Laguna; Elspeth McDougall; Jaime Landman
Clinical, pathologic, and functional outcomes after nephron-sparing surgery in patients with a solitary kidney: a multicenter experience.
Journal of endourology / Endourological Society 2012;26(10):1361-6.
2012: Alessandro Volpe; Antonio Finelli; Inderbir S Gill; Michael A S Jewett; Guido Martignoni; Thomas J Polascik; Mesut Remzi; Robert G Uzzo
Rationale for percutaneous biopsy and histologic characterisation of renal tumours.
European urology 2012;62(3):491-504.
2012: Michael R Abern; Thomas J Polascik; M Tsivian; Christopher L Coogan
Characteristics and outcomes of tumors arising from the distal nephron.
Urology 2012;80(1):140-6.
2012: Jorge R Caso; Vladimir Mouraviev; Matvey Tsivian; Thomas J Polascik
Predicting biopsy-proven prostate cancer recurrence following cryosurgery.
Urologic oncology 2012;30(4):391-5.
2012: M Tsivian; Michael R Abern; Thomas J Polascik
Prostate cancer treatment unblinded.
The lancet oncology 2012;13(6):567-8.
2012: Masaki Kimura; Craig F Donatucci; Isabel Jackson; Judd W Moul; Thomas J Polascik; Zahid Rabbani; Zeljko Vujaskovic; Hui Yan; Andrew R Zodda; Bridget F Koontz
Role of oxidative stress in a rat model of radiation-induced erectile dysfunction.
The journal of sexual medicine 2012;9(6):1535-49.
2012: Hashim U Ahmed; Oguz Akin; Jonathan A Coleman; Sarah Crane; Mark Emberton; Larry Goldenberg; Hedvig Hricak; Mike W Kattan; John Kurhanewicz; Caroline M Moore; Chris Parker; Thomas J Polascik; Peter Scardino; Nicholas van As; Arnauld Villers
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.
BJU international 2012;109(11):1636-47.
2012: Daniel A Wattson; Michelle H Braccioforte; Ming-Hui Chen; Daniel E Dosoretz; Brian J Moran; Judd W Moul; Thomas J Polascik; Cary N Robertson; Sharon A Salenius; Anthony V D'Amico
The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection.
International journal of radiation oncology, biology, physics 2012;82(5):e773-9.
2012: Michael R Abern; M Tsivian; Thomas J Polascik
Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria.
Current urology reports 2012;13(2):160-9.
2012: Masaki Kimura; Shiro Baba; Lionel L Bañez; Stephen J Freedland; Leah Gerber; Thomas J Polascik; Jim Qi; Takefumi Satoh; Matvey Tsivian; Judd W Moul
Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database.
The journal of sexual medicine 2012;9(4):1174-81.
2012: Matvey Tsivian; Michael D Rosenberg; Jorge R Caso; Charles Y Kim; Rendon C Nelson; Thomas J Polascik
Contrast enhancement on computed tomography after renal cryoablation: an evidence of treatment failure?
Journal of endourology / Endourological Society 2012;26(4):330-5.
2012: Jorge R Caso; Masaki Kimura; Vladimir Mouraviev; Matvey Tsivian; Thomas J Polascik
Complications and postoperative events after cryosurgery for prostate cancer.
BJU international 2012;109(6):840-5.
2012: John M Baust; Andrew A Gage; Daniel P Klossner; Vladimir Mouraviev; Thomas J Polascik; Anthony Robilotto; Robert G VanBuskirk; John G Baust
Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis.
BJU international 2012;109(6):949-58.
2012: Matvey Tsivian; Terrence Wong; Tiera Wright; Marva Price; Masaki Kimura; John F Madden; Vladimir Mouraviev; Thomas J Polascik
111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer.
Urologic oncology 2012;30(2):150-4.
2012: Maria Azrad; Dean E Brenner; Robert W Hardy; John Madden; Judd W Moul; Thomas J Polascik; Mack T Ruffin; Denise Clutter Snyder; Robin T Vollmer; Kui Zhang; Wendy Demark-Wahnefried
Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: a relationship which may depend on genetic variation in ALA metabolism.
PloS one 2012;7(12):e53104.
2012: Qiang Fu; Judd W Moul; Vladimir Mouraviev; Leon Sun; Donghua Xie; Lionel L Bañez; Thomas J Polascik
Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy.
Urologia internationalis 2012;89(3):296-300.
2012: Liang Zhai; Wen-Chi Foo; John Madden; Mark L Palmeri; Thomas J Polascik; Stephen Rosenzweig; Kathryn R Nightingale
Acoustic radiation force impulse imaging of human prostates: initial in vivo demonstration.
Ultrasound in medicine & biology 2012;38(1):50-61.
2012: Matvey Tsivian; Leon Sun; Masaki Kimura; Daniel M Moreira; Judd W Moul; Vladimir Mouraviev; Thomas J Polascik
Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight.
Urologic oncology 2012;30(1):21-5.
2011: Masaki Kimura; Judd W Moul; Shiro Baba; Lionel L Bañez; Craig F Donatucci; Leah Gerber; Jim Qi; Cary N Robertson; Takefumi Satoh; Florian R Schroeck; Philip J Walther; Thomas J Polascik
Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy.
The journal of sexual medicine 2011;8(10):2935-43.
2011: John V Heymach; Ajaikumar B Kunnumakkara; Thomas J Polascik; Mack T Ruffin; Pierre Saintigny; Terry J Shackleford; Denise Clutter Snyder; Hai T Tran; Robin T Vollmer; Melanie Wergin; Shaoyu Yan; Suk-Young Yoo; Bharat B Aggarwal; Mark Dewhirst; Kim-Anh Do; Wendy Demark-Wahnefried
Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer.
Cancer prevention research (Philadelphia, Pa.) 2011;4(10):1590-8.
2011: Hein Van Poppel; Frank Becker; Jeffrey A Cadeddu; Inderbir S Gill; Gunther Janetschek; Michael A S Jewett; M Pilar Laguna; Michael Marberger; Francesco Montorsi; Thomas J Polascik; Osamu Ukimura; Gang Zhu
Treatment of localised renal cell carcinoma.
European urology 2011;60(4):662-72.
2011: Vladimir Mouraviev; David G Bostwick; Rodolfo Montironi; Arnauld Villers; Thomas M Wheeler; Thomas J Polascik
Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy.
BJU international 2011;108(7):1074-85.
2011: Shane E Cotter; Mitchell S. Anscher; Ming Hui Chen; Bridget F Koontz; W Robert Lee; Judd W Moul; Thomas J Polascik; Cary N Robertson; Philip J Walther; Anthony V D'Amico
Salvage radiation in men after prostate-specific antigen failure and the risk of death.
Cancer 2011;117(17):3925-32.
2011: Matvey Tsivian; Thomas J Polascik
The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy.
BJU international 2011;108(3):371.
2011: Matvey Tsivian; Jorge R Caso; Masaki Kimura; Thomas J Polascik
Renal function outcomes after laparoscopic renal cryoablation.
Journal of endourology / Endourological Society 2011;25(8):1287-91.
2011: Masaki Kimura; Shiro Baba; Craig F Donatucci; Thomas J Polascik; Zahid Rabbani; Takefumi Satoh; Zeljko Vujaskovic; Hui Yan; Fang-fang Yin; Bridget F Koontz
Radiation-induced erectile dysfunction using prostate-confined modern radiotherapy in a rat model.
The journal of sexual medicine 2011;8(8):2215-26.
2011: Ping Tang; Matthew A Uhlman; Thomas J Polascik; Cary N Robertson; Leon Sun; Judd W Moul
Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men.
BJU international 2011;108(1):44-8.
2011: Matvey Tsivian; Daniel M Moreira; Jorge R Caso; Vladimir Mouraviev; Thomas J Polascik
Cigarette smoking is associated with advanced renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2027-31.
2011: Tsivian Matvey; Thomas J Polascik
Editorial comment.
Urology 2011;77(5):1152-3; author reply 1153-4.
2011: Michael D Rosenberg; Charles Y Kim; Matvey Tsivian; Matthew N Suberlak; David R Sopko; Thomas J Polascik; Rendon C Nelson
Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications.
AJR. American journal of roentgenology 2011;196(4):935-9.
2011: M Kimura; Craig F Donatucci; M Tsivian; Jorge R Caso; D M Moreira; Vladimir Mouraviev; T Satoh; S Baba; Thomas J Polascik
On-demand use of erectile aids in men with preoperative erectile dysfunction treated by whole gland prostate cryoablation.
International journal of impotence research 2011;23(2):49-55.
2011: Matvey Tsivian; Vladimir Mouraviev; David M Albala; Jorge R Caso; Cary N Robertson; John F Madden; Thomas J Polascik
Clinical predictors of renal mass pathological features.
BJU international 2011;107(5):735-40.
2011: Janice M Mayes; Vladimir Mouraviev; Leon Sun; Matvey Tsivian; John F Madden; Thomas J Polascik
Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer?
Urologic oncology 2011;29(2):166-70.
2011: Vladimir Mouraviev; Thomas J Polascik
New Frontiers in Imaging and Focal Therapy: Highlights From the Third International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer, February 24-27, 2010, Washington, DC.
Reviews in urology 2011;13(2):104-11.
2010: Jorge R Caso; Matvey Tsivian; Vladimir Mouraviev; Thomas J Polascik; Judd W Moul
Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer.
BJU international 2010;106(11):1623-7.
2010: Anthony V D'Amico; Ming-Hui Chen; Leon Sun; W Robert Lee; Vladimir Mouraviev; Cary N Robertson; Philip J Walther; Thomas J Polascik; David M Albala; Judd W Moul
Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death.
BJU international 2010;106(11):1618-22.
2010: Ping Tang; Leon Sun; Matthew A Uhlman; Cary N Robertson; Thomas J Polascik; David M Albala; Craig F Donatucci; Judd W Moul
Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.
Urology 2010;76(5):1058-62.
2010: Masaki Kimura; Vladimir Mouraviev; Matvey Tsivian; Daniel M Moreira; Janice M Mayes; Thomas J Polascik
Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoablation.
Urology 2010;76(5):1258-65.
2010: Ping Tang; Leon Sun; Matthew A Uhlman; Thomas J Polascik; Stephen J Freedland; Judd W Moul
Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience.
Cancer 2010;116(20):4711-7.
2010: Liang Zhai; John Madden; Wen-Chi Foo; Vladimir Mouraviev; Thomas J Polascik; Mark L Palmeri; Kathryn R Nightingale
Characterizing stiffness of human prostates using acoustic radiation force.
Ultrasonic imaging 2010;32(4):201-13.
2010: Arthur A Caire; Leon Sun; Thomas J Polascik; David M Albala; Judd W Moul
Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans.
BJU international 2010;106(8):1157-60.
2010: Matvey Tsivian; Thomas J Polascik
Editorial comment.
Urology 2010;76(3):687; discussion 687-8.
2010: Masaki Kimura; Zahid Rabbani; Vladimir Mouraviev; Matvey Tsivian; Jorge R Caso; Takefumi Satoh; Shiro Baba; Zeljko Vujaskovic; John M Baust; John G Baust; Thomas J Polascik
Role of vitamin D(3) as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study.
Urology 2010;76(3):764.e14-20.
2010: A A Caire; Leon Sun; B D Lack; K Lum; P Tang; D A Stackhouse; Cary N Robertson; Vladimir Mouraviev; Thomas J Polascik; David M Albala; Judd W Moul
Predicting non-organ-confined prostate cancer in men diagnosed after 2000.
Prostate cancer and prostatic diseases 2010;13(3):248-51.
2010: Masaki Kimura; Zahid Rabbani; Vladimir Mouraviev; Matvey Tsivian; Zeljko Vujaskovic; Takefumi Satoh; Shiro Baba; John M Baust; John G Baust; Thomas J Polascik
Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and, microvessel density.
Cryobiology 2010;61(1):148-54.
2010: Scott E Eggener; Georg Salomon; Peter T Scardino; Jean De la Rosette; Thomas J Polascik; Simon Brewster
Focal therapy for prostate cancer: possibilities and limitations.
European urology 2010;58(1):57-64.
2010: Matvey Tsivian; Valerie H Chen; Charles Y Kim; Dorit E Zilberman; Vladimir Mouraviev; Rendon C Nelson; David M Albala; Thomas J Polascik
Complications of laparoscopic and percutaneous renal cryoablation in a single tertiary referral center.
European urology 2010;58(1):142-7.
2010: Matvey Tsivian; Daniel M Moreira; Jorge R Caso; Vladimir Mouraviev; John F Madden; Gennady Bratslavsky; Cary N Robertson; David M Albala; Thomas J Polascik
Predicting occult multifocality of renal cell carcinoma.
European urology 2010;58(1):118-26.
2010: Vladimir Mouraviev; Truls Erik Bjerklund Johansen; Thomas J Polascik
Contemporary results of focal therapy for prostate cancer using cryoablation.
Journal of endourology / Endourological Society 2010;24(5):827-34.
2010: Matvey Tsivian; Thomas J Polascik
Focal cryotherapy for prostate cancer.
Current urology reports 2010;11(3):147-51.
2010: Matvey Tsivian; Marcel Hruza; Vladimir Mouraviev; Jens Rassweiler; Thomas J Polascik
Prostate biopsy in selecting candidates for hemiablative focal therapy.
Journal of endourology / Endourological Society 2010;24(5):849-53.
2010: Jorge R Caso; Vladimir Mouraviev; Matvey Tsivian; Thomas J Polascik; Judd W Moul
Prostate cancer: an evolving paradigm.
Journal of endourology / Endourological Society 2010;24(5):805-9.
2010: Arthur A Caire; Leon Sun; Cary N Robertson; Thomas J Polascik; Kelly E Maloney; Daniel J George; Marva M Price; Danielle A Stackhouse; Benjamin D Lack; David M Albala; Judd W Moul
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.
Urology 2010;75(5):1122-7.
2010: Toni K Choueiri; Ming-Hui Chen; Anthony V D'Amico; Leon Sun; Paul L Nguyen; Julia H Hayes; Cary N Robertson; Philip J Walther; Thomas J Polascik; David M Albala; Judd W Moul
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.
Cancer 2010;116(8):1887-92.
2010: Liang Zhai; John Madden; Wen-Chi Foo; Mark L Palmeri; Vladimir Mouraviev; Thomas J Polascik; Kathryn R Nightingale
Acoustic radiation force impulse imaging of human prostates ex vivo.
Ultrasound in medicine & biology 2010;36(4):576-88.
2010: Matvey Tsivian; Leon Sun; Masaki Kimura; Janice M Mayes; Vladimir Mouraviev; Thomas J Polascik
Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended.
BJU international 2010;105(8):1089-92.
2010: Matthew A Uhlman; Leon Sun; Danielle A Stackhouse; Thomas J Polascik; Vladimir Mouraviev; Cary N Robertson; David M Albala; Judd W Moul
Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.
The Journal of urology 2010;183(3):997-1001.
2010: Ping Tang; Leon Sun; Matthew A Uhlman; Cary N Robertson; Thomas J Polascik; David M Albala; Craig F Donatucci; Judd W Moul
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
The Journal of urology 2010;183(3):946-50.
2010: Matvey Tsivian; John C Lyne; Janice M Mayes; Vladimir Mouraviev; Masaki Kimura; Thomas J Polascik
Tumor size and endophytic growth pattern affect recurrence rates after laparoscopic renal cryoablation.
Urology 2010;75(2):307-10.
2010: Matthew A Uhlman; Leon Sun; Danielle A Stackhouse; Arthur A Caire; Thomas J Polascik; Cary N Robertson; John Madden; Robin Vollmer; David M Albala; Judd W Moul
Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?
Urology 2010;75(2):460-6.
2010: Matvey Tsivian; Thomas J Polascik
Recent advances in focal therapy of prostate and kidney cancer.
F1000 medicine reports 2010;2():.
2010: Masaki Kimura; Vladimir Mouraviev; Matvey Tsivian; Janice M Mayes; Takefumi Satoh; Thomas J Polascik
Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy.
BJU international 2010;105(2):191-201.
2009: Masaki Kimura; Matvey Tsivian; Vladimir Mouraviev; Janice M Mayes; Marva M Price; Michael C Bannister; John F Madden; Terence Z Wong; Thomas J Polascik
Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy.
International journal of urology : official journal of the Japanese Urological Association 2009;16(12):971-5.
2009: Matvey Tsivian; Janice M Mayes; Tracey L Krupski; Vladimir Mouraviev; Craig F Donatucci; Thomas J Polascik
Altered male physiologic function after surgery for prostate cancer: couple perspective.
International braz j urol : official journal of the Brazilian Society of Urology 2009;35(6):673-82.
2009: Leon Sun; Arthur A Caire; Cary N Robertson; Daniel J George; Thomas J Polascik; Kelly E Maloney; Philip J Walther; Danielle A Stackhouse; Benjamin D Lack; David M Albala; Judd W Moul
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
The Journal of urology 2009;182(5):2242-8.
2009: Matvey Tsivian; Leon Sun; Vladimir Mouraviev; John F Madden; Janice M Mayes; Judd W Moul; Thomas J Polascik
Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy.
Urology 2009;74(5):1090-3.
2009: Thomas J Polascik; Vladimir Mouraviev
Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients.
Urology 2009;74(4):726-30.
2009: David D Xu; Sandy D Sun; Flint Wang; Leon Sun; Danielle Stackhouse; Thomas J Polascik; David M Albala; Judd W Moul; Arthur Caire; Cary N Robertson
Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.
Urology 2009;74(3):654-8.
2009: Vladimir Mouraviev; John F Madden; Gloria Broadwater; Janice M Mayes; James L Burchette; Frank Schneider; Jill Smith; Matvey Tsivian; Terence Wong; Thomas J Polascik
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland.
The Journal of urology 2009;182(3):938-47.
2009: Arthur A Caire; Leon Sun; Oludotun Ode; Danielle A Stackhouse; Kelly Maloney; Craig F Donatucci; Vladimir Mouraviev; Thomas J Polascik; Cary N Robertson; David M Albala; Judd W Moul
Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?
Urology 2009;74(3):643-7.
2009: Richard C D'Alonzo; Tong J Gan; Judd W Moul; David M Albala; Thomas J Polascik; Cary N Robertson; Leon Sun; Philipp Dahm; Ashraf S Habib
A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy.
Journal of clinical anesthesia 2009;21(5):322-8.
2009: Janice M Mayes; Vladimir Mouraviev; M Tsivian; T L Krupski; Craig F Donatucci; Thomas J Polascik
Concordance in the perception of couples recovering from primary surgical treatment of prostate cancer.
International journal of impotence research 2009;21(4):253-60.
2009: Danielle A Stackhouse; Leon Sun; Florian R Schroeck; Jayakrishnan Jayachandran; Arthur A Caire; Cyril O Acholo; Cary N Robertson; David M Albala; Thomas J Polascik; Craig F Donatucci; Kelly E Maloney; Judd W Moul
Factors predicting prostatic biopsy Gleason sum under grading.
The Journal of urology 2009;182(1):118-22; discussion 123-4.
2009: Ashraf S Habib; Thomas J Polascik; Alon Z Weizer; William D White; Judd W Moul; Magdi A ElGasim; Tong J Gan
Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy.
Anesthesia and analgesia 2009;108(6):1950-3.
2009: Thomas J Polascik; Janice M Mayes; Florian R Schroeck; Leon Sun; John F Madden; Judd W Moul; Vladimir Mouraviev
Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.
Cancer 2009;115(10):2104-10.
2009: Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Pathologic basis of focal therapy for early-stage prostate cancer.
Nature reviews. Urology 2009;6(4):205-15.
2009: Valerie H Chen; Vladimir Mouraviev; Janice M Mayes; Leon Sun; John F Madden; Judd W Moul; Thomas J Polascik
Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection.
Technology in cancer research & treatment 2009;8(2):99-104.
2009: Judd W Moul; Vladimir Mouraviev; Leon Sun; Florian R Schroeck; Thomas J Polascik
Prostate cancer: the new landscape.
Current opinion in urology 2009;19(2):154-60.
2009: Thomas J Polascik; Janice M Mayes; Vladimir Mouraviev
Nerve-sparing focal cryoablation of prostate cancer.
Current opinion in urology 2009;19(2):182-7.
2009: Thomas J Polascik
Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases.
Drug design, development and therapy 2009;3():27-40.
2008: Wendy Demark-Wahnefried; Thomas J Polascik; Stephen L George; Boyd R Switzer; John F Madden; Mack T Ruffin; Denise Clutter Snyder; Kouros Owzar; Vera Hars; David M Albala; Philip J Walther; Cary N Robertson; Judd W Moul; Barbara K Dunn; Dean E Brenner; Lori Minasian; Philip Stella; Robin T Vollmer
Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(12):3577-87.
2008: Florian R Schroeck; Craig F Donatucci; Emily C Smathers; Leon Sun; David M Albala; Thomas J Polascik; Judd W Moul; Tracey L Krupski
Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite.
Cancer 2008;113(10):2687-94.
2008: Alexandra J Stein; Janice M Mayes; Vladimir Mouraviev; Valerie H Chen; Rendon C Nelson; Thomas J Polascik
Persistent contrast enhancement several months after laparoscopic cryoablation of the small renal mass may not indicate recurrent tumor.
Journal of endourology / Endourological Society 2008;22(11):2433-9.
2008: Florian R Schroeck; Tracey L Krupski; Leon Sun; David M Albala; Marva M Price; Thomas J Polascik; Cary N Robertson; Alok K Tewari; Judd W Moul
Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy.
European urology 2008;54(4):785-93.
2008: Brandon K Isariyawongse; Leon Sun; Lionel L Bañez; Cary Robertson; Thomas J Polascik; Kelly Maloney; Craig F Donatucci; David Albala; Vladimir Mouraviev; John F Madden; Judd W Moul
Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen.
Urology 2008;72(4):882-6.
2008: Thomas J Polascik; Janice M Mayes; Leon Sun; John F Madden; Judd W Moul; Vladimir Mouraviev
Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
The Prostate 2008;68(13):1380-6.
2008: Ashraf S Habib; William D White; Magdi A El Gasim; Gamal Saleh; Thomas J Polascik; Judd W Moul; Tong J Gan
Transdermal nicotine for analgesia after radical retropubic prostatectomy.
Anesthesia and analgesia 2008;107(3):999-1004.
2008: Valerie H Chen; Janice M Mayes; Vladimir Mouraviev; Thomas J Polascik
Urothelial sloughing with obstruction after laparoscopic cryoablation of small renal carcinoma in solitary kidney.
Urology 2008;72(3):716.e1-2.
2008: Ifeanyichukwu I Megwalu; Genoa G Ferguson; John T Wei; Vladimir Mouraviev; Thomas J Polascik; Samir Taneja; Linda Black; Gerald L Andriole; Adam S Kibel
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer.
BJU international 2008;102(5):546-50.
2008: Janice M Mayes; Vladimir Mouraviev; Thomas J Polascik
Impact of a cryotherapy training workshop on the adoption and utilization of cryotherapy in the community setting.
The Canadian journal of urology 2008;15(4):4147-52.
2008: Valerie H Chen; Janice M Mayes; John F Madden; Alexandra J Stein; Vladimir Mouraviev; Thomas J Polascik
The effect of cryoablation on the histologic interpretation of intraoperative biopsy of small clear cell renal carcinoma and renal oncocytoma.
Journal of endourology / Endourological Society 2008;22(8):1617-21.
2008: Thomas J Polascik; Janice M Mayes; Vladimir Mouraviev
From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer.
Oncology (Williston Park, N.Y.) 2008;22(8):900-6; discussion 906-7, 914.
2008: Florian R Schroeck; Leon Sun; Stephen J Freedland; David M Albala; Vladimir Mouraviev; Thomas J Polascik; Judd W Moul
Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy.
BJU international 2008;102(1):28-32.
2008: Vladimir Mouraviev; Gloria Broadwater; Leon Sun; Janice M Mayes; Judd W Moul; Thomas J Polascik
Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?
Urology 2008;71(6):1020-3.
2008: Bridget F Koontz; Vladimir Mouraviev; Jeffrey L Johnson; Janice Mayes; Stephanie H Chen; Terence Z Wong; Mitchell S. Anscher; Leon Sun; Judd Moul; Thomas J Polascik
Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
International journal of radiation oncology, biology, physics 2008;71(2):358-61.
2008: Thomas J Polascik; Vladimir Mouraviev
Focal therapy for prostate cancer.
Current opinion in urology 2008;18(3):269-74.
2008: Thomas J Polascik; Vladimir Mouraviev
Zoledronic acid in the management of metastatic bone disease.
Therapeutics and clinical risk management 2008;4(1):261-8.
2008: Wendy Demark-Wahnefried; Stephen L George; Boyd R Switzer; Denise C Snyder; John F Madden; Thomas J Polascik; Mack T Ruffin; Robin T Vollmer
Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer.
Clinical trials (London, England) 2008;5(3):262-72.
2008: Thomas J Polascik
Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.
Prostate cancer and prostatic diseases 2008;11(1):13-9.
2007: Vladimir Mouraviev; Leon Sun; John F Madden; Janice M Mayes; Judd W Moul; Thomas J Polascik
Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.
Urology 2007;70(6):1141-5.
2007: Thomas J Polascik; Israel Nosnik; Janice M Mayes; Vladimir Mouraviev
Short Term Clinical Outcome after Laparoscopic Cryoablation of the Renal Tumor < or = 3.5 cm.
Technology in cancer research & treatment 2007;6(6):621-4.
2007: Thomas J Polascik; Vladimir Mouraviev
The rise of ablative technologies for treating the small renal mass.
European urology 2007;52(3):636-8.
2007: Vladimir Mouraviev; Janice M Mayes; Leon Sun; John F Madden; Judd W Moul; Thomas J Polascik
Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.
Cancer 2007;110(4):906-10.
2007: Stephanie H Chen; Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Prostatic abscess as a delayed complication following cryosurgery for primary prostate cancer.
The Canadian journal of urology 2007;14(4):3646-8.
2007: Thomas J Polascik; Israel Nosnik; Janice M Mayes; Vladimir Mouraviev
Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology.
Urology 2007;70(1):117-21.
2007: Stephanie H Chen; Vladimir Mouraviev; Ganesh V Raj; Charles G Marguet; Thomas J Polascik
Ureteropelvic junction obliteration resulting in nephrectomy after radiofrequency ablation of small renal cell carcinoma.
Urology 2007;69(5):982.e3-5.
2007: Charles G Marguet; Ganesh V Raj; James H Brashears; Mitchell S. Anscher; Kirk Ludwig; Vladimir Mouraviev; Cary N Robertson; Thomas J Polascik
Rectourethral fistula after combination radiotherapy for prostate cancer.
Urology 2007;69(5):898-901.
2007: Timothy Y Tseng; Quinton V Cancel; Susan F Fesperman; Hubert R Kuebler; Leon Sun; Cary N Robertson; Thomas J Polascik; Judd W Moul; Zhen Su; David M Albala; Philipp Dahm
The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy.
The Journal of urology 2007;177(4):1318-23.
2007: Vladimir Mouraviev; Janice M Mayes; John F Madden; Leon Sun; Thomas J Polascik
Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy.
Technology in cancer research & treatment 2007;6(2):91-5.
2007: Leon Sun; Judd W Moul; James M Hotaling; Edward Rampersaud; Philipp Dahm; Cary Robertson; Nicholas J Fitzsimons; David M Albala; Thomas J Polascik
Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
BJU international 2007;99(4):753-7.
2007: Vladimir Mouraviev; Israel Nosnik; Cary Robertson; David M Albala; Philip J Walther; Thomas J Polascik
Comparative financial analysis of minimally invasive surgery to open surgery for small renal tumours < or =3.5 cm: a single institutional experience.
European urology 2007;51(3):715-20; discussion 720-1.
2007: Vladimir Mouraviev; Israel Nosnik; Leon Sun; Cary N Robertson; Philip J Walther; David M Albala; Judd W Moul; Thomas J Polascik
Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience.
Urology 2007;69(2):311-4.
2007: Judd W Moul; Leon Sun; James M Hotaling; Nicholas J Fitzsimons; Thomas J Polascik; Cary N Robertson; Philipp Dahm; Mitchell S. Anscher; Vladimir Mouraviev; Paul A Pappas; David M Albala
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
The Journal of urology 2007;177(2):499-503; discussion 503-4.
2007: Vladimir Mouraviev; Steven Joniau; Hendrik Van Poppel; Thomas J Polascik
Current status of minimally invasive ablative techniques in the treatment of small renal tumours.
European urology 2007;51(2):328-36.
2006: Brian K Auge; Robert W Santa-Cruz; Thomas J Polascik
Effect of freeze time during renal cryoablation: a swine model.
Journal of endourology / Endourological Society 2006;20(12):1101-5.
2006: Ganesh V Raj; Charles A Yowell; John F Madden; Israel Nosnik; Vladimir Mouraviev; Thomas J Polascik
Malignant cystic nephroma.
The Canadian journal of urology 2006;13(6):3348-50.
2006: Israel Nosnik; Vladimir Mouraviev; Rendon Nelson; Thomas J Polascik
Multiple nephron-sparing procedures in solitary kidney with recurrent, metachronous, nonfamilial renal cell carcinoma.
Urology 2006;68(6):1343.e1-3.
2006: Jeremy B Wiygul; Costas D Lallas; Ari D Silverstein; Thomas J Polascik
Ovarian hyperstimulation causing ureteral obstruction in a pregnant woman.
Urology 2006;67(5):1085.e5-6.
2006: Vladimir Mouraviev; Thomas J Polascik
Update on cryotherapy for prostate cancer in 2006.
Current opinion in urology 2006;16(3):152-6.
2006: Vladimir Mouraviev; B Evans; Thomas J Polascik
Salvage prostate cryoablation after primary interstitial brachytherapy failure: a feasible approach.
Prostate cancer and prostatic diseases 2006;9(1):99-101.
2005: Alon Z Weizer; Ganesh V Raj; Martin O'Connell; Cary N Robertson; Rendon C Nelson; Thomas J Polascik
Complications after percutaneous radiofrequency ablation of renal tumors.
Urology 2005;66(6):1176-80.
2005: Thomas J Polascik; Robert W Given; Charles Metzger; Sydney R Julian; James C Vestal; Gary S Karlin; Craig S Barkley; David L Bilhartz; Laura T McWhorter; Leo V Lacerna
Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
Urology 2005;66(5):1054-9.
2005: Jeremy B Wiygul; Brian R Evans; Bercedis L Peterson; Thomas J Polascik; Philip J Walther; Cary N Robertson; David M Albala; Wendy Demark-Wahnefried
Supplement use among men with prostate cancer.
Urology 2005;66(1):161-6.
2005: James H Brashears; Ganesh V Raj; Alfonso Crisci; Matthew D Young; Drew Dylewski; Rendon Nelson; John F Madden; Thomas J Polascik
Renal cryoablation and radio frequency ablation: an evaluation of worst case scenarios in a porcine model.
The Journal of urology 2005;173(6):2160-5.
2005: Ganesh V Raj; James H Brashears; Ankur Anand; David F Paulson; Thomas J Polascik
Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy?
Urology 2005;65(2):332-6.
2005: Terence Z Wong; Timothy G Turkington; Thomas J Polascik; R Edward Coleman
ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology.
AJR. American journal of roentgenology 2005;184(2):676-80.
2004: Essel Dulaimi; Inmaculada Ibanez de Caceres; Robert G Uzzo; Tahseen Al-Saleem; Richard E Greenberg; Thomas J Polascik; James S Babb; William E Grizzle; Paul Cairns
Promoter hypermethylation profile of kidney cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):3972-9.
2004: Wendy Demark-Wahnefried; Cary N Robertson; Philip J Walther; Thomas J Polascik; David F Paulson; Robin T Vollmer
Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen.
Urology 2004;63(5):900-4.
2003: Ganesh V Raj; Kenneth S Ellington; Thomas J Polascik
Autoimmune testicular vasculitis.
Urology 2003;61(5):1035.
2003: Robert W Santa-Cruz; Brian K Auge; Costas D Lallas; Glenn M Preminger; Thomas J Polascik
Use of bipolar laparoscopic forceps to occlude and transect the retroperitoneal vasculature: a porcine model.
Journal of endourology / Endourological Society 2003;17(3):181-5.
2003: Ganesh V Raj; Donal J Reddan; Michael F Hoey; Michael B Hoey; Thomas J Polascik
Management of small renal tumors with radiofrequency ablation.
Urology 2003;61(1):23-9.
2002: Thomas J Polascik; David G Bostwick; Paul Cairns
Molecular genetics and histopathologic features of adult distal nephron tumors.
Urology 2002;60(6):941-6.
2002: Ravi Munver; Chris B Threatt; Fernando C Delvecchio; Glenn M Preminger; Thomas J Polascik
Hypertonic saline-augmented radiofrequency ablation of the VX-2 tumor implanted in the rabbit kidney: a short-term survival pilot study.
Urology 2002;60(1):170-5.
2002: David T Price; R Edward Coleman; Ray P Liao; Cary N Robertson; Thomas J Polascik; Timothy R DeGrado
Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
The Journal of urology 2002;168(1):273-80.
2002: Ganesh V Raj; Alan W Partin; Thomas J Polascik
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Cancer 2002;94(4):987-96.
2001: Wendy Demark-Wahnefried; David T Price; Thomas J Polascik; Cary N Robertson; E Everett Anderson; David F Paulson; Philip J Walther; M Gannon; Robin T Vollmer
Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features.
Urology 2001;58(1):47-52.
2001: Donal N Reddan; G V Raj; Thomas J Polascik
Management of small renal tumors: an overview.
The American journal of medicine 2001;110(7):558-62.
2001: Timothy R DeGrado; R Edward Coleman; Shuyan Wang; Steven W Baldwin; M D Orr; Cary N Robertson; Thomas J Polascik; David T Price
Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
Cancer research 2001;61(1):110-7.
2000: Ravi Munver; Ross C Donehower; J D Kronz; Thomas J Polascik
HIV infection presenting as an unusually large pure yolk sac tumor of the testis.
The Journal of urology 2000;164(5):1653-4.